MAO-B inhibition with selegiline has been shown to reduce oxidative stress and improve various conditions, including obesity (Nagy et al., 2018) and cardiac disease (Qin et al., 2003; Takahata et al., 2006). Here, MAOB is linked to obesity disorder.